The US Oncology Network has announced the launch of a new groundbreaking program that was developed to aid oncologists from around the country prepare for the execution of the new Centers for Medicare & Medicaid Services (CMS) Oncology Care Model (OCM) and other alternate payment models. Read More »

The Generic Pharmaceutical Association (GPhA) and its Biosimilars Council has released a statement from its President and CEO, Chip Davis, commending the International Generic and Biosimilar Medicines Association (IGBA) for persuading the World Health Organization (WHO) to carry out an evaluation of the global impact for the voluntary biologic qualifier (BQ) proposal for the quality, safety and access to biologic products. Read More »

Taiho Pharmaceutical announced last week that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended LONSURF for the treatment of metastatic colorectal cancer (mCRC) in adults. Read More »

The U.S. Food and Drug Administration (FDA) recently approved a new indication for the Novartis drug, Afinitor (everolimus). Read More »

The American Society of Health-System Pharmacists (ASHP) announced earlier this week that it has published new guidelines for pharmacists who are currently involved with HIV care. Read More »

Verseon Corp. has released new data for a promising class of anticoagulants that was presented at the Third International Conference on Heart & Brain (ICHB) in Paris at the end of February. Read More »

Opiant Pharmaceuticals Inc. announced this week that it has received $2.5 million from Adapt Pharma Ltd. as a milestone payment following Adapt’s first commercial sale of NARCAN Nasal Spray. Read More »

Merck, or MSD outside of the United States and Canada, has named Sanat Chattopadhyay as its new EVP and president of Merck Manufacturing Division (MMD). Read More »

Citius Pharmaceuticals announced this week that it has agreed to buy all outstanding shares of Leonard Meron Biosciences (LMB). Read More »

CVS Health announced this week that it has extended the access of naloxone, its opioid overdose-reversal medication, in its CVS Pharmacy locations to include eight additional states. Read More »

Halozyme Therapeutics Inc. announced today that it has selected Jim Daily to join its board of directors. Read More »

Aimmune Therapeutics Inc. recently revealed data from the open-label ARC002 Phase 2 trial for its product, AR101, designed to treat peanut allergies. Read More »

Sanofi US and Regeneron Pharmaceuticals Inc. announced last week that the two companies will receive exclusive or preferred access to Praluent (alirocumab) injections from Humana for commercial and Medicare patients. Read More »

Allergan recently announced the launch of its innovative new program, LILETTA + LILETTA Patient Commitment Program, which will allow patients who are eligible the opportunity to acquire a second LILETTA at no cost to them. Read More »

The top 15 pharmacies of 2015, ranked by total U.S. prescription dispensing revenues, are largely central-fill, mail and specialty pharmacies, according to a recent article released by the Drug Channels Institute. Read More »

Cipher Pharmaceuticals Inc. has appointed Ralph Bohrer as the president and general manager of its subsidiary located in the United States. Read More »

Altan Pharma Ltd. announced this week the signing of a licensure agreement that will commercialize a generic version of caspofungin. Read More »

The American Society of Health-System Pharmacists (ASHP) has published a guide called "The Pharmacist’s Guide to Antimicrobial Therapy and Stewardship" to assist health care providers in fighting antimicrobial resistance to guarantee that patients are given the best treatments. Read More »

Astellas Pharma Inc. this week announced personnel changes for the company. Read More »

Amgen announced earlier this week that it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) that will include new information to support the treatment of pediatric and adolescent patients who have been diagnosed with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Read More »